FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michel Tod

Research Profile

Concepts & Ideas

Physiology

Chemicals & Drugs

Procedures

Activities & Behaviors

Computer Simulation

Phenomena

Protein Binding

Co-author Network

Publications

TOP 3
Sylvain Goutelle; Johanna Berry; Nathalie Bleyzac; Laurent Bourguignon; Fannie Clavel-Grabit; Michel Tod
In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.
Anne-Charlotte Castellan; François Gueyffier; Behrouz Kassaï; Patrice Nony; Michel Tod; Mélanie Audars; Fredéric Cambriels
Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Ines Paule; Gilles Freyer; Pascal Girard; Michel Tod
Pharmacodynamic models for discrete data.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michel Tod (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sylvain Goutelle; Johanna Berry; Nathalie Bleyzac; Laurent Bourguignon; Fannie Clavel-Grabit; Michel Tod
In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.
The AAPS journal 2013;15(2):415-26.
2013: Anne-Charlotte Castellan; François Gueyffier; Behrouz Kassaï; Patrice Nony; Michel Tod; Mélanie Audars; Fredéric Cambriels
Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Clinical pharmacokinetics 2013;52(3):199-209.
2012: Ines Paule; Gilles Freyer; Pascal Girard; Michel Tod
Pharmacodynamic models for discrete data.
Clinical pharmacokinetics 2012;51(12):767-86.
2012: Juliane Preuss; Michel Tod; Christian Ducerf; Serge Duperret; Mathieu Gazon; Jean-Yves Mabrut; Salim Mezoughi; Bruno Charpiat
Tacrolimus trough levels before, during and after jejunostomy in a liver transplant patient: a case report.
Clinics and research in hepatology and gastroenterology 2012;36(6):e126-30.
2012: Marilyne Hornecker; Olivier Mir; Stanislas Ropert; Hind Sassi; Fabrice Taieb; Halim Abbas; Bertrand Billemont; Benoit Blanchet; Romain Coriat; Alain Dauphin; François Goldwasser; Laura Harcouet; Michel Tod
Saturable absorption of sorafenib in patients with solid tumors: a population model.
Investigational new drugs 2012;30(5):1991-2000.
2012: Benjamin Ribba; Damien Ricard; Michel Tod; Branka Cajavec-Bernard; Vincent Calvez; Stéphanie Cartalat-Carel; Linda Dainese; Jean-Yves Delattre; Emmanuel Grenier; Jérôme Honnorat; Ahmed Idbaih; Gentian Kaloshi; Johan Pallud; Mathieu Peyre; Dimitri Psimaras; François Ducray
A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(18):5071-80.
2012: V Jullien; Michel Tod; M Benyamina; B Blanchet; Christophe Vinsonneau
Pharmacokinetics of caspofungin in two patients with burn injuries.
Antimicrobial agents and chemotherapy 2012;56(8):4550-1.
2012: N Pécuchet; Michel Tod; M Viguier; C Lebbe; Olivier Mir; M-F Avril; Bertrand Billemont; B Blanchet; R Coriat; N Franck; François Goldwasser
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
British journal of cancer 2012;107(3):455-61.
2012: Bruno Charpiat; Agnès Henry; G Leboucher; Michel Tod; B Allenet
Overdosed prescription of paracetamol (acetaminophen) in a teaching hospital.
Annales pharmaceutiques françaises 2012;70(4):213-8.
2012: Audrey Janoly-Dumenil; Florence Morfin; Isabelle Rouvet; Nathalie Bleyzac; Marie-Therese Zabot; Michel Tod
A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.
Antimicrobial agents and chemotherapy 2012;56(7):3732-8.
2012: Ines Paule; Michel Tod; Benoit You; Gilles Freyer; Emilie Hénin; Pascal Girard
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Cancer chemotherapy and pharmacology 2012;69(2):447-55.
2012: Pascaline Boudou-Rouquette; Laure Cabanes; Romain Coriat; Nathalie Franck; Bertrand Billemont; Benoit Blanchet; Olivier Mir; Stanislas Ropert; Michel Tod; François Goldwasser
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
The oncologist 2012;17(9):1204-12.
2011: Michel Tod; Michel Vidal; Halim Abbas; Natacha Bancelin; Pascaline Boudou-Rouquette; Romain Coriat; Alain Dauphin; Jean Philippe Durand; Francois Goldwasser; Judith Michels; Olivier Mir; Stanislas Ropert; Fabrice Taieb; Audrey Thomas-Schoemann; Benoit Blanchet
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
Pharmaceutical research 2011;28(12):3199-207.
2011: Charline Gomo; Olivier Mir; Stanislas Ropert; Michel Tod; Romain Coriat; Alain Dauphin; Lionel Faivre; François Goldwasser; Bertrand Billemont; Benoit Blanchet
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Investigational new drugs 2011;29(6):1511-4.
2011: Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.
Pharmaceutical research 2011;28(3):531-9.
2011: Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.
Journal of pharmacokinetics and pharmacodynamics 2011;38(1):25-40.
2011: Odile Launay; Valériane Leroy; Olivier Lortholary; Ali Si-Mohamed; Anne-Marie Taburet; Michel Tod; Inga Tschöpe; Linda Bélarbi; Laurent Bélec; Charlotte Charpentier; Cécile Goujard
Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.
Antiviral therapy 2011;16(6):843-52.
2011: Ines Paule; Kim Pd Pham; Hind Sassi; Dora Bachir; Frédéric Galactéros; Pascal Girard; Anoosha Habibi; Anne Hulin; Michel Tod
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
Orphanet journal of rare diseases 2011;6():30.
2010: Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.
Pharmaceutical research 2010;27(12):2602-13.
2010: Benoit You; Ludivine Fronton; Helen Boyle; Jean-Pierre Droz; Pascal Girard; Brigitte Tranchand; Benjamin Ribba; Michel Tod; Sylvie Chabaud; Henri Coquelin; Aude Fléchon
Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
Urology 2010;76(2):423-9.e2.
2009: Benoit You; Pascal Girard; Philippe Paparel; Gilles Freyer; Alain Ruffion; Anne Charrié; Emilie Hénin; Michel Tod; Paul Perrin
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.
The Prostate 2009;69(12):1325-33.
2009: Benoit Blanchet; Carole Saboureau; Anne Sophie Benichou; Bertrand Billemont; Fabrice Taieb; Stanislas Ropert; Alain Dauphin; François Goldwasser; Michel Tod
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Clinica chimica acta; international journal of clinical chemistry 2009;404(2):134-9.
2009: Anne Hulin; Benoit Blanchet; Vincent Audard; Caroline Barau; Valérie Furlan; Antoine Durrbach; Fabrice Taïeb; Philippe Lang; Philippe Grimbert; Michel Tod
Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients.
Therapeutic drug monitoring 2009;31(2):224-32.
2008: Michel Tod
Evaluation of drugs in pediatrics using K-PD models: perspectives.
Fundamental & clinical pharmacology 2008;22(6):589-94.
2008: Benoit Blanchet; Fabrice Taieb; Filomena Conti; Halim Abbas; Idrissa Seydi; Laura Harcouet; Alain Dauphin; Yvon Calmus; Michel Tod
Comparison of a new enzymatic assay with a high-performance liquid chromatography/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2008;14(12):1745-51.
2008: Benjamin Silbermann; Michel Tod; Corinne Desaint; Gilles Pialoux; Karine Petitprez; Laurence Slama; Hubert Poncelet; Corinne Moreau; Veronique Mazarin; Farad Heshmati; Dominique Salmon-Ceron; Jean-Gerard Guillet; Odile Launay
Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers.
AIDS research and human retroviruses 2008;24(11):1445-8.
2008: Marie-Claude Gagnieu; Mirna El Barkil; Jean-Michel Livrozet; Laurent Cotte; Patrick Miailhes; André Boibieux; Jérôme Guitton; Michel Tod
Population pharmacokinetics of tenofovir in AIDS patients.
Journal of clinical pharmacology 2008;48(11):1282-8.
2008: Benoit You; Brigitte Tranchand; Pascal Girard; Claire Falandry; Benjamin Ribba; Sylvie Chabaud; Pierre-Jean Souquet; Isabelle Court-Fortune; Véronique Trillet-Lenoir; Cécile Fournel; Michel Tod; Gilles Freyer
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Lung cancer (Amsterdam, Netherlands) 2008;62(2):261-72.
2008: Olivier Lortholary; Agnès Lefort; Michel Tod; Anne-Marie Chomat; Clémence Darras-Joly; Catherine Cordonnier
Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia.
The Lancet infectious diseases 2008;8(10):612-20.
2008: Benoit Blanchet; Christophe Duvoux; Charlotte E Costentin; Camille Barrault; Bijan Ghaleh; Annie Salvat; Hélène Jouault; alain astier; Michel Tod; Anne Hulin
Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period.
Therapeutic drug monitoring 2008;30(4):412-8.
2008: Benoit You; Paul Perrin; Gilles Freyer; Alain Ruffion; Brigitte Tranchand; Emilie Hénin; Philippe Paparel; Benjamin Ribba; Marian Devonec; Claire Falandry; Cécile Fournel; Michel Tod; Pascal Girard
Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.
Clinical biochemistry 2008;41(10-11):785-95.
2008: Michel Tod; Franck Lagneau; Vincent Jullien; Olivier Mimoz
A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate.
Pharmaceutical research 2008;25(6):1431-9.
2008: Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Clinical pharmacokinetics 2008;47(10):635-54.
2008: Michel Tod; Vincent Jullien; Gérard Pons
Facilitation of drug evaluation in children by population methods and modelling.
Clinical pharmacokinetics 2008;47(4):231-43.
2007: Céline Dartois; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Michel Tod; Pascal Girard
Evaluation of uncertainty parameters estimated by different population PK software and methods.
Journal of pharmacokinetics and pharmacodynamics 2007;34(3):289-311.
2007: Bérangère Gruwez; Marie-France Poirier; Alain Dauphin; Jean-Pierre Olié; Michel Tod
A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction.
Contemporary clinical trials 2007;28(3):276-87.
2006: Michel Tod
[Pharmacokinetic of antifungal drugs in order to optimize their administration].
Thérapie 2006;61(3):219-25.
2005: Bérangère Gruwez; Alain Dauphin; Michel Tod
A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Journal of pharmacokinetics and pharmacodynamics 2005;32(5-6):663-83.
2005: M Le Jouan; Vincent Jullien; E Tetanye; Agnès Tran; Elisabeth Rey; Jean-Marc Tréluyer; Michel Tod; Gérard Pons
Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum.
Antimicrobial agents and chemotherapy 2005;49(9):3658-62.
2005: Tim R Cressey; Prattana Leenasirimakul; Gonzague Jourdain; Michel Tod; Pra-Ornsuda Sukrakanchana; Suparat Kunkeaw; Chutima Puttimit; Marc Lallemant
Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
The Journal of antimicrobial chemotherapy 2005;55(6):1041-4.
2005: Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.
Journal of pharmacokinetics and pharmacodynamics 2005;32(1):1-32.
2005: Michel Tod; Muriel Farcy-Afif; Jeanick Stocco; Nathalie Boyer; Valérie Bouton; Martine Sinègre; Patrick Marcellin
Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
Clinical pharmacokinetics 2005;44(4):417-28.
2004: Franck Lagneau; Michel Tod; Jean Marty
[Clinical applications of intravenous anaesthetics pharmacology: the example of hypnotics and opioids].
Annales françaises d'anesthèsie et de rèanimation 2004;23(10):986-97.
2004: François Audren; Michel Tod; Pascale Massin; Rym Benosman; Belkacem Haouchine; Ali Erginay; Charles Caulin; alain gaudric; Jean-François Bergmann
Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema.
Investigative ophthalmology & visual science 2004;45(10):3435-41.
2004: Sam Bayat; Kamel Louchahi; B Verdière; Daniel Anglade; A Rahoui; P M Sorin; Michel Tod; Olivier Petitjean; F Fraisse; FA Grimbert
Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2004;24(1):150-6.
2004: Yann Merlé; Azzedine Aouimer; Michel Tod
Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies.
Journal of biopharmaceutical statistics 2004;14(1):213-27.
2004: Odile Launay; Michel Tod; Kamel Louchahi; Linda Belarbi; Olivier Bouchaud; Nathalie Mémain; Olivier Petitjean; Michel Robineau; Loïc Guillevin; Olivier Lortholary
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
Antimicrobial agents and chemotherapy 2004;48(2):632-4.
2003: Valérie Martinez; Jean-Luc Le Guillou; Christian Lamer; Melissande Le Jouan; Michel Tod; Françoise Dromer
Serum voriconazole levels following administration via percutaneous jejunostomy tube.
Antimicrobial agents and chemotherapy 2003;47(10):3375.
2003: M Leone; Jacques Albanèse; Michel Tod; V Savelli; E Ragni; D Rossi; Claude Martin
Ceftriaxone (1 g intravenously) penetration into abdominal tissues when administered as antibiotic prophylaxis during nephrectomy.
Journal of chemotherapy (Florence, Italy) 2003;15(2):139-42.
2002: F De Bony; Michel Tod; Roselyne Bidault; NT On; J Posner; PE Rolan
Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir.
Antimicrobial agents and chemotherapy 2002;46(2):458-63.
2002: Michel Tod; Azzedine Aouimer; Olivier Petitjean
Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
Computer methods and programs in biomedicine 2002;67(1):13-26.
2001: Yann Merlé; Michel Tod
Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
Journal of pharmacokinetics and pharmacodynamics 2001;28(4):363-88.
2001: Olivier Mimoz; V Schaeffer; P Incagnoli; Kamel Louchahi; Alain R Edouard; Olivier Petitjean; Michel Tod
Co-amoxiclav pharmacokinetics during posttraumatic hemorrhagic shock.
Critical care medicine 2001;29(7):1350-5.
2001: M Bouley; C Briere; C Padoin; Olivier Petitjean; Michel Tod
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
Therapeutic drug monitoring 2001;23(1):56-60.
2001: Michel Tod; C Padoin; Olivier Petitjean
Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
Clinical pharmacokinetics 2001;40(11):803-14.
2001: Michel Tod; F Lokiec; Roselyne Bidault; F De Bony; Olivier Petitjean; Y Aujard
Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.
Antimicrobial agents and chemotherapy 2001;45(1):150-7.
2000: Olivier Mimoz; S Soreda; C Padoin; Michel Tod; Olivier Petitjean; Dan Benhamou
Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs.
Anesthesiology 2000;93(3):735-43.
2000: L Belfayol-Pisanté; L Guillevin; Michel Tod; F Fauvelle
Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Fundamental & clinical pharmacology 2000;14(4):415-21.
2000: F Fauvelle; Olivier Petitjean; Michel Tod; L Guillevin
Clinical pharmacokinetics during plasma exchange.
Thérapie 2000;55(2):269-75.
2000: Michel Tod; C Padoin; Olivier Petitjean
Clinical pharmacokinetics and pharmacodynamics of isepamicin.
Clinical pharmacokinetics 2000;38(3):205-23.
1999: Michel Tod; C Minozzi; Gilles Beaucaire; D Ponsonnet; J Cougnard; Olivier Petitjean
Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.
The Journal of antimicrobial chemotherapy 1999;44(1):99-108.
1999: Olivier Lortholary; M Nicolas; S Soreda; Luce Improvisi; Olivier Ronin; Olivier Petitjean; Bertrand Dupont; Michel Tod; Françoise Dromer
Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.
The Journal of antimicrobial chemotherapy 1999;43(6):817-24.
1999: Anne Jacolot; P Incagnoli; Alain R Edouard; Michel Tod; Olivier Petitjean; K Samii; Olivier Mimoz
Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Intensive care medicine 1999;25(5):486-91.
1998: Michel Tod; France Mentré; Yann Merlé; A Mallet
Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):689-716.
1998: P Nicolas; Michel Tod; C Padoin; Olivier Petitjean
Clinical pharmacokinetics of diacerein.
Clinical pharmacokinetics 1998;35(5):347-59.
1998: Olivier Mimoz; V Binter; Anne Jacolot; Alain R Edouard; Michel Tod; Olivier Petitjean; K Samii
Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.
Intensive care medicine 1998;24(10):1047-51.
1998: C Padoin; Michel Tod; gerard PERRET; Olivier Petitjean
Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.
Antimicrobial agents and chemotherapy 1998;42(6):1463-9.
1998: Michel Tod; Olivier Lortholary; D Seytre; R Semaoun; B UZZAN; L Guillevin; Philippe Casassus; Olivier Petitjean
Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Antimicrobial agents and chemotherapy 1998;42(4):849-56.
1998: Olivier Mimoz; Anne Jacolot; C Padoin; Michel Tod; K Samii; Olivier Petitjean
Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
The Journal of antimicrobial chemotherapy 1998;41(3):367-72.
1997: Michel Tod; P Alet; Olivier Lortholary; Olivier Petitjean
Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.
Journal of pharmacokinetics and biopharmaceutics 1997;25(6):695-712.
1997: Michel Tod; J M Rocchisani
Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
Journal of pharmacokinetics and biopharmaceutics 1997;25(4):515-37.
1997: Olivier Mimoz; Anne Jacolot; C Padoin; J Caillon; Kamel Louchahi; Michel Tod; K Samii; Olivier Petitjean
Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
The Journal of antimicrobial chemotherapy 1997;39(3):363-9.
1997: B Durand-Gasselin; Olivier Lortholary; Michel Tod; Loïc Guillevin; Philippe Casassus
Efficacy of teicoplanin in Staphylococcus aureus catheter-related tricuspid endocarditis during severe neutropenia.
Annales de médecine interne 1997;148(7):502-3.
1996: Michel Tod; J M Rocchisani
Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.
Computer methods and programs in biomedicine 1996;50(1):13-22.
1996: Anne Jacolot; Michel Tod; A M Heudes; Olivier Petitjean; L Laroche
Monitoring of 8-methoxypsoralen during extracorporeal photochemotherapy: evidence for a "first-dose" effect.
Therapeutic drug monitoring 1996;18(3):234-9.
1996: O Lortholary; Michel Tod; N Rizzo; C Padoin; O Biard; Philippe Casassus; Loïc Guillevin; Olivier Petitjean
Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
Antimicrobial agents and chemotherapy 1996;40(5):1242-7.
1996: Michel Tod; C Padoin; C Minozzi; J Cougnard; Olivier Petitjean
Population pharmacokinetic study of isepamicin with intensive care unit patients.
Antimicrobial agents and chemotherapy 1996;40(4):983-7.
1996: Anne Jacolot; Michel Tod; Olivier Petitjean
Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.
Antimicrobial agents and chemotherapy 1996;40(4):979-82.
1996: Olivier Mimoz; Anne Jacolot; C Padoin; J Quillard; Michel Tod; K Louchahi; K Samii; Olivier Petitjean
Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics.
Antimicrobial agents and chemotherapy 1996;40(3):819-21.
1995: Michel Tod; C Pobel; Vincent Le Gros; K Louchahi; Olivier Petitjean; N Brion; J L Garcia-Mace
A population pharmacokinetic study of alminoprofen penetration into synovial fluid.
Biopharmaceutics & drug disposition 1995;16(8):627-34.
1995: S L Tamisier-Karolak; Michel Tod; P Bonnardel; M Czok; P Cardot
Daily validation procedure of chromatographic assay using gaussoexponential modelling.
Journal of pharmaceutical and biomedical analysis 1995;13(8):959-70.
1995: Olivier Petitjean; Michel Tod; K Louchahi
Influence of methodological aspects on tissue drug concentration estimation.
Journal of pharmaceutical and biomedical analysis 1995;13(7):817-22.
1995: C Padoin; Michel Tod; N Brion; K Louchahi; Vincent Le Gros; Olivier Petitjean
Pharmacokinetics of amoxicillin coadministered with a saline-polyethylene glycol solution in healthy volunteers.
Biopharmaceutics & drug disposition 1995;16(3):169-76.
1995: K Louchahi; Michel Tod; P Bonnardel; Olivier Petitjean
Determination of piracetam in human plasma and urine by liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;663(2):385-9.
1994: M Bouley; Michel Tod; P Chavanet; Olivier Petitjean
The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis.
Biopharmaceutics & drug disposition 1994;15(6):485-92.
1994: F Fauvelle; O Lortholary; Michel Tod; L Guillevin; M Louchahi; A Léon; Olivier Petitjean
Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients.
Antimicrobial agents and chemotherapy 1994;38(7):1519-22.
1994: Michel Tod; C Padoin; K Louchahi; B Moreau-Tod; Olivier Petitjean; gerard PERRET
Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.
Journal of pharmacokinetics and biopharmaceutics 1994;22(2):129-46.
1994: F Fauvelle; P Perrin; L Belfayol; M Boukari; P Cherrier; A M Bosio; Michel Tod; J M Coulaud; Olivier Petitjean
Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics.
Antimicrobial agents and chemotherapy 1994;38(3):620-3.
1994: P Debord; K Louchahi; Michel Tod; A Cournot; gerard PERRET; Olivier Petitjean
Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.
European journal of drug metabolism and pharmacokinetics 1994;19(1):13-9.
1993: J Oliary; Michel Tod; K Louchahi; Olivier Petitjean; B Frachet; Vincent Le Gros; N Brion
Influence of local radiotherapy on penetration of fluconazole into human saliva.
Antimicrobial agents and chemotherapy 1993;37(12):2674-7.
1993: O Magnard; K Louchahi; Michel Tod; Olivier Petitjean; P Molinier; laurent berdah; gerard PERRET
Pharmacokinetics of diacerein in patients with liver cirrhosis.
Biopharmaceutics & drug disposition 1993;14(5):401-8.
1993: Olivier Petitjean; Béatrice Pangon; N Brion; Michel Tod; C Chaplain; Vincent Le Gros; K Louchahi; Pierre Allouch
Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.
Antimicrobial agents and chemotherapy 1993;37(4):737-40.
1993: P Cherrier; Michel Tod; Vincent Le Gros; Olivier Petitjean; N Brion; A Chatelin
Cefotiam concentrations in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(3):211-5.
1993: P Nicolas; Michel Tod; Olivier Petitjean
[Review and use of decision rules for bioequivalence trials].
Thérapie 1993;48(1):15-22.
1993: P Debord; K Louchahi; Michel Tod; P Molinier; laurent berdah; gerard PERRET; Olivier Petitjean
Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.
Fundamental & clinical pharmacology 1993;7(8):435-41.
1992: J Oliary; Michel Tod; P Nicolas; Olivier Petitjean; G Caillé
Pharmacokinetics of ibuprofen enantiomers after single and repeated doses in man.
Biopharmaceutics & drug disposition 1992;13(5):337-44.
1992: Olivier Petitjean; J L Wendling; Michel Tod; K Louchahi; P Nicolas; gerard PERRET; alain astier
Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis.
Alimentary pharmacology & therapeutics 1992;6(3):351-7.
1992: L Karolak; Michel Tod; A Leon; A M Heudes; Olivier Petitjean; L Laroche
In vitro kinetics of 8-methoxypsoralen penetration into human lymphoid cells.
Photodermatology, photoimmunology & photomedicine 1992;9(2):58-60.
1992: Michel Tod; O Biarez; P Nicolas; Olivier Petitjean
Sensitive determination of josamycin and rokitamycin in plasma by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;575(1):171-6.
1992: N Vermerie; D Kusielewicz; Michel Tod; P Nicolas; gerard PERRET; F Fauvelle; Olivier Petitjean
Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers.
Fundamental & clinical pharmacology 1992;6(4-5):197-203.
1992: F Fauvelle; A Léon; P Nicolas; Michel Tod; L Guillevin; Olivier Petitjean
Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa.
Fundamental & clinical pharmacology 1992;6(1):11-5.
1991: F Fauvelle; P Nicolas; A Leon; Michel Tod; gerard PERRET; Olivier Petitjean; L Guillevin
Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients.
Biopharmaceutics & drug disposition 1991;12(6):411-24.
1991: F Fauvelle; Olivier Petitjean; Michel Tod; P Nicolas; A Leon; L Guillevin
[Extraction of drugs in plasma exchange].
Thérapie 1991;46(2):109-13.
1991: B Tod; G Chaine; J Oliary; F Mezzanotte; Michel Tod; Olivier Petitjean
[Penetration of cefixime in the anterior chamber of the human eye].
Journal français d'ophtalmologie 1991;14(8-9):477-80.